This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

VIFNZ Stock Overview

VIFNZ fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 8.73% per year

Earnings grew by 5.7% over the past year

Risk Analysis

Latest financial reports are more than 6 months old

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Vifor Pharma AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vifor Pharma
Historical stock prices
Current Share Price	CHF 166.00
52 Week High	CHF 197.10
52 Week Low	CHF 157.75
Beta	1.04
1 Month Change	-2.09%
3 Month Change	-6.87%
1 Year Change	1.84%
3 Year Change	n/a
5 Year Change	32.91%
Change since IPO	62.75%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	VIFNZ	GB Pharmaceuticals	GB Market
7D	0.3%	2.9%	2.1%
1Y	1.8%	-12.6%	1.8%

Return vs Industry: VIFNZ exceeded the UK Pharmaceuticals industry which returned -7.1% over the past year.

Return vs Market: VIFNZ exceeded the UK Market which returned -2.4% over the past year.

Price Volatility

Is VIFNZ's price volatile compared to industry and market?
VIFNZ volatility
VIFNZ Average Weekly Movement	2.2%
Pharmaceuticals Industry Average Movement	7.3%
Market Average Movement	5.9%
10% most volatile stocks in GB Market	11.2%
10% least volatile stocks in GB Market	3.2%

Stable Share Price: VIFNZ has not had significant price volatility in the past 3 months.

Volatility Over Time: VIFNZ's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1872	2,200	n/a	www.viforpharma.com

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD) It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis.

Vifor Pharma AG Fundamentals Summary

How do Vifor Pharma's earnings and revenue compare to its market cap?
VIFNZ fundamental statistics
Market cap	CHF 10.78b
Earnings (TTM)	CHF 146.60m
Revenue (TTM)	CHF 1.81b

73.1x

P/E Ratio

5.9x

P/S Ratio

Is VIFNZ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIFNZ income statement (TTM)
Revenue	CHF 1.81b
Cost of Revenue	CHF 671.80m
Gross Profit	CHF 1.14b
Other Expenses	CHF 993.70m
Earnings	CHF 146.60m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	2.26
Gross Margin	62.93%
Net Profit Margin	8.09%
Debt/Equity Ratio	13.6%

How did VIFNZ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/12/25 03:15
End of Day Share Price	2022/12/22 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vifor Pharma AG is covered by 20 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Armelle Moulin	AlphaValue
Jean-Philippe Bertschy	Bank Vontobel AG
Rosie Turner	Barclays